STRENGTHENING EXISTING CAPACITIES
EXPANDING AND CONSOLIDATING CLINICAL RESEARCH CAPACITIES
In line with its vision and mission, DNDi has worked closely with partners in disease-endemic countries to strengthen existing clinical research capacity and build new capacity where necessary. transfers, particularly of manufacturing processes, to industrial partners in endemic regions. The technology transfer of the antimalarial A SAQ – developed in partnership with Sanofi and others – to the Tanzanian drug company Zenufa, made significant progress in 2015. This required stability and bioequivalence studies, together with the preparation of the WHO prequalification and registration dossier to be submitted in 2016 which could ultimately result in the production of three to five million treatments per year for distribution in Africa.
The year 2015 has been a time for consolidation of the three existing platforms – LEAP, HAT Platform, and CCRP, which have been highly involved in clinical studies, treatment access, and personnel training – as well as of the recently created RedeLEISH network, which took off with a dense programme of activities mainly for R&D for cutaneous leishmaniasis.
DNDi has always been committed to putting in place processes that, if successful, will ensure a wide-spread distribution of new treatments, and maintain competitive prices, such as by the development of non-patented products. The technological and scientific capacities of endemic countries have been reinforced, including through technology
56 › DNDi Annual Report 2015